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Abstract
Background: Breast and cervical cancers represent a significant cause of morbidity and mortality among women. The
purpose of this study was to analyse the survival and time trends in two of the most common female cancers in the
Regional Health District (RHD) of Barretos, São Paulo, Brazil.
Methods: From 2000 through 2015, we calculated the breast and cervical cancer incidence and mortality rates per
100,000 women who were age-standardized to the world population. We obtained the time trends using the
Joinpoint Regression software. We estimated the overall survival rates using the Kaplan-Meier methods.
Results: The age-standardized rates (ASR) for incidence of breast cancer increased annually, with an average annual
percentage change (AAPC) of 4.3 (95% Confidence Interval (CI): 2.4 to 6.3) for invasive breast cancer and 10.2 (95% CI: 6.
1 to 14.5) for in situ breast cancer. The mortality rates for invasive breast cancer decreased with an AAPC of 0.2 (95% CI:
-1.9 to 2.4). The ASR incidence of invasive cervical cancer showed an AAPC of − 1.9 (95% CI: -4.7 to 0.9). For in situ
cases, the ASR showed an AAPC of 9.3 (95% CI: 3.3 to 15.7). The ASR mortality for cervical cancer showed an AAPC of −
5.3 (95% CI: -9.5 to − 0.8). The Kaplan-Meier analysis indicated 5-year overall survival rates of 74.3% for breast cancer and
70.7% for cervical cancer.
Conclusions: The incidence of in situ and invasive breast cancer is increasing, while the mortality rates remain stable.
We observed an increase in the incidence of in situ cervical cancer and a decrease in invasive incidence rates during
the study period, and we noted that the cervical cancer mortality significantly declined during the study period.
Keywords: Breast neoplasms, Gynaecologic neoplasms, Breast cancer, Cervix cancer, Epidemiology of chronic diseases,
Mortality, Incidence, Trends
Background
Breast and cervical cancers are a significant cause of mor-
bidity and mortality among women. Breast cancer is the
most frequently diagnosed cancer (1.7 million) and the
leading cause of cancer death (521,900 deaths) among
women worldwide. Cervical cancer ranks fourth as the
most frequently diagnosed type of cancer (527,600 new
cases) among women worldwide, while in low- to
middle-income countries, it is the second most commonly
diagnosed type of cancer and the third leading cause of
cancer death (265,700 deaths) among women [1].
There is a substantial variation in the incidence rates of
breast and cervical cancers in different countries that may
reflect the differences in the availability of early detection
and screening services, as well as the differences in risk fac-
tors [1–3]. Mammography screening can often detect
breast cancer at an earlier stage when treatment is more
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efficient, and the cure rate is higher, thereby decreasing
mortality in a population [4]. For cervical cancer, such vari-
ation may be explained by the differences in the availability
of screening techniques, allowing the detection and re-
moval of precancerous lesions and the human papillomavi-
rus (HPV) infection [1, 3, 5, 6]. In high-income countries,
the Pap smear test is the most common screening method
for cervical cancer. In low-resource countries, the most effi-
cient and cost-effective screening techniques are visual in-
spection using acetic acid and HPV tests [7]. HPV vaccines
Gardasil [Merck and Company, Whitehouse Station, NJ]
and Cervarix [Glaxo Smith Kline, Brentford, UK] are avail-
able for protection against exposure to the most common
risk of HPV for cervical cancers.
In Brazil, few studies have evaluated temporal cancer
trends. Of these studies, Ayres et al. [8] showed an in-
creasing trend of in situ and invasive cervical cancer in 4
capitals of Brazil in the period between 1990 and 2004.
Lima et al. [9] showed an increasing incidence trend for
breast cancer in the mid-sized northeastern Brazilian
city, Aracaju, from 1996 to 2006. Several studies evaluat-
ing the temporal mortality trend showed a cervical can-
cer decrease and an increase or stable rate of the breast
cancer over time [10–12].
The incidence of cancer can be evaluated using
Population-Based Cancer Registries. There are 26 official
cancer registries in operation (at least for one consoli-
dated year) in Brazil, of which 19 are located in capitals,
one in the Federal District, one with state coverage and
another five in non-capital cities [13]. The Ministry of
Health through the Brazilian National Cancer Institute
(Instituto Nacional do Câncer – INCA) has been advan-
cing the population-based cancer registry since its cre-
ation in the 1960s, focusing on non-capital cities, to
establish how this chronic disease behaves in the interior
of the country. To date, there have been no previous
evaluations of the incidence and mortality trends in the
Barretos region. We analysed the overall survival and
time trends in the incidence of breast and cervical can-
cers and the mortality rate (2000–2015) among women
using population-based cancer registry data for the RHD
of Barretos, São Paulo state, Brazil.
Methods
The current study was to describe the cancer incidence and
mortality time trends. The State of São Paulo (Brazil) is ad-
ministratively divided into 17 Regional Health Districts
(RHDs). The RHD is responsible for coordinating activities
at the regional level and promoting inter-sectorial articula-
tion, with municipalities and civil society organisations [14].
RHD-V (Additional file 1: Figure S1) comprises 18 cities lo-
cated in the Northeast of State of São Paulo State (Altair,
Barretos, Bebedouro, Cajobi, Colina, Colômbia, Guaíra,
Guaraci, Jaborandi, Monte Azul Paulista, Olímpia,
Severínia, Taiaçu, Taiúva, Taquaral, Terra Roxa, Viradouro,
and Vista Alegre do Alto), including both rural and urban
populations, with 434,939 inhabitants (2017). According to
the medium human development index (HDI), which com-
prises gross national income, education attainment, and life
expectancy at birth, Brazil is high in the ranks [15]. The
Barretos Cancer Hospital is responsible for the activities of
the Population-Based Cancer Registry covering RHD-V,
suitably called the “Population-Based Cancer Registry of
Barretos Cancer Hospital.”
The Population-Based Cancer Registry of Barretos Can-
cer Hospital actively collected cancer cases from public
and private sources such as hospitals, diagnostic and treat-
ment clinics, pathology laboratories, units that provided
comprehensive cancer treatment and followed the cancer
classification rules recommended by the International
Agency for Research on Cancer (IARC) as defined by the
INCA. The methods of diagnosis were as follows: hist-
ology, cytology, imaging, clinical and laboratory evidence,
and surgical findings. There was a careful review to verify
the case data source as RHD of Barretos. Case duplicity
was managed by Cancer Registry software [16] (SisBase-
Pop, developed by INCA), which checked the information
in several sources and databases. Classification and coding
were performed according to the International Classifica-
tion of Diseases for Oncology, 3rd edition (ICD-3) [17].
The International Classification of Diseases, 10th edition
(ICD-10) was used as a coding standard for incidence and
mortality. The topography considered was C50 (invasive
breast cancer), D05 (in situ breast cancer), C53 (invasive
cervical cancer) and D06 (in situ cervical cancer).
We calculated breast and cervical cancer incidence rates
from 2000 to 2015 using data from the Population-Based
Cancer Registry of Barretos Cancer Hospital, and breast
and cervical cancer mortality rates from 2000 to 2015
using data from the Official Federal Database (DATASUS)
(http://datasus.saude.gov.br/). The population references
we used were based on the age distribution for the 18 cit-
ies belonging to the RHD-V (2000–2010). The DATASUS
website provided intercensal estimates.
All data were stored in “.csv” format, which allowed
for versatile data management using Microsoft Excel
2013 (Microsoft Corporation 2013) and Joinpoint Re-
gression software, version 4.5.0.1 (June 2017; Statistical
Methodology and Applications Branch, Surveillance Re-
search Program, National Cancer Institute, EUA). Both
incidence and mortality rates per 100,000 women were
age-standardized, using the direct method, according to
the world population [18–20]. A mortality-to-incidence
ratio of ASRs was obtained to assess the burden of these
two cancers. The time trends were obtained by calculat-
ing the average annual percentage change (AAPC) and
95% confidence interval (CI) for breast and cervical can-
cer incidence and mortality using log-linear Poisson
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regression. The overall survival (OS) rates were esti-
mated in months of life accrued using the Kaplan-Meier
method, and survival was defined as the period from the
date of diagnosis to the time of death or the date at
which information was last obtained from the patient.
For the analysis, the event of interest was death. Cases
that were alive were censored. Log-rank test was used to
compare the survival curves. Cox regression estimated
the hazard ratios. The chi-squared test was used to ana-
lyse by period and clinical stage the proportional differ-
ences in cases and deaths. For statistical analysis, we
used IBM® SPSS® Statistics 20.0.1 software for Windows
(IBM Corporation, Route 100, Somers, NY). The level of
statistical significance was set at 0.05 for all analyses.
Results
During the study period, 2110 new incident cases of breast
cancer and 978 cases of cervical cancer were reported to
the registry. A total of 477 breast and 136 cervical neo-
plasms deaths were detected in the mortality database.
The characteristics of incident cases are shown in Table 1.
The incidence and mortality rates per 100,000 women
are shown in Table 2, and the incidence and mortality
trend curves are displayed in Figs. 1 and 2. The incidence
rates for in situ breast cancer increased from 1.55/100,000
in year 2000 to 16.04/100,000 in year 2015 (AAPC: 10.2;
95% CI: 6.1 to 14.5) and for invasive breast cancer, the in-
cidence rates increased from 29.09/100,000 in year 2000
to 64.09/100,000 in year 2015 (AAPC: 4.3; 95% CI: 2.4 to
6.3). Age-standardized incidence rates increased signifi-
cantly. The mortality rates for invasive breast cancer were
10.4/100,000 in year 2000 and 14.00/100,000 in year 2015
(AAPC of 0.2; 95% CI: -1.9 to 2.4). The age-standardized
incidence rates for in situ cervical cases were 10.90/
100,000 in year 2000 and 24.84/100,000 in year 2015
(AAPC: 9.3; 95% CI: 3.3 to 15.7). For invasive cervical can-
cer, the age-standardized incidence rates were 10.67/
100,000 in year 2000 and 8.87/100,000 in year 2015
(AAPC: -1.9; 95% CI: -4.7 to 0.9). For cervical cancer mor-
tality, the age-standardized incidence rates varied from
4.32/100,000 in year 2000 to 3.13/100,000 in year 2015
(AAPC: -5.3; 95% CI: -9.5 to − 0.8). The mean
mortality-to-incidence ratio for the time series was 0.27
for breast cancer and 0.37 for cervical cancer.
The clinical stage of disease at the time of diagnosis
(TNM) versus the year of diagnosis is shown in Add-
itional file 1: Table S1. A considerable reduction in stage
IV cervical cancer disease was observed from 23.5 to
9.2% by 2015. The Kaplan-Meier analysis indicated a
5-year OS rate of 74.3% for breast cancer and 70.7% for
cervical cancer. The patients diagnosed in the period
ranging from 2000 to 2004 had the lowest OS rate
(breast cancer: p = 0.058; cervical cancer: p = 0.004); and
clinical stages III/IV had the lowest OS rates (p < 0.001
for breast and cervical cancers). The distributions of
cases according to the patients’ characteristics and OS
are shown with more detail in Table 3, and the OS
curves are shown in Additional file 1: Figures S2 and S3.
Discussion
We found an increase in the incidence of both in situ and
invasive breast cancer as well as a decrease in invasive cer-
vical cancer from 2000 to 2015. While in situ cervical can-
cer increased during the period, a reduction of cervical
cancer mortality was observed. Improvements in survival
and cancer burden as reflected in mortality-to-incidence
ratios were observed for both cancers. These findings are
exciting because both breast and cervical cancer screening
programmes were implemented around the same period
in the RHD of Barretos, compared to many high-income
countries performing nationwide screening before the
study period. Thus, the increased incidence for these two
cancers and the decreased mortality for cervical cancer
may have been primarily influenced by screening pro-
grammes although treatment access may have also played
Table 1 Characteristics of the incidence of breast and cervical
cancer cases according to Population-Based Cancer Registry of
Barretos Cancer Hospital, São Paulo, Brazil, years 2000–2015
Variable Breast cancer Cervical cancer
N % N %
Age at diagnosis
< 30 years 22 1.0 219 22.4
30–39 years 128 6.1 224 22.9
40–49 years 502 23.8 189 19.3
≥50 years 1458 69.1 346 35.4
School levela
Illiterate 158 7.8 82 8.8
<High school 1292 63.9 676 72.4
High school 295 14.6 109 11.7
College 276 13.7 67 7.2
Year of diagnosis
2000–2004 410 19.4 242 24.7
2005–2009 596 28.2 185 18.9
2010–2015 1104 52.3 551 56.6
Clinical stage of disease at diagnosis (breast cancer: TNM; cervical
cancer: FIGO)a
In situ 338 16.5 619 65.9
I 468 22.9 84 8.9
II 649 31.8 91 9.7
III 405 19.8 94 10.0
IV 183 9.0 51 5.4
Total 2110 100 978 100
aNumbers in these variables do not add up to the overall total number of
cases due to the missing values
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a role. There was an increase in early diagnosis (in situ
cases) for breast and cervical cancers and a decrease in
the mortality rate for cervical cancer.
In Brazil, INCA [2] estimated in 2016 that 56 cases of
breast cancer and 16 cases of cervical cancer would
occur in every 100,000 women. For the state of São
Paulo, 69 cases of breast cancer and 9 cases of cervical
cancer were estimated to occur in every 100,000 women.
Taking an average of the last 3 years detailed in the
present study, the RHD of Barretos showed an incidence
rate similar to that predicted by INCA, 61 cases of
breast cancer and 10 cases of cervical cancer in every
100,000 women. Likewise, previous studies observed a
decrease in cervical cancer mortality throughout the
period and a decline in breast cancer mortality from
1990 to 2010.
Breast cancer screening practices in Brazil include bi-
annual mammography for women aged 50 to 69 years
with nationwide follow-up as outlined by the Brazilian
National Cancer Institute (Instituto Nacional do Câncer
- INCA) [21]. The present study shows a significantly in-
creased incidence rate for in situ and invasive breast
cancer, especially after the opportunistic mammography
screening programme of Barretos Cancer Hospital
implementation that started in 2003 in the RHD of Bar-
retos (São Paulo) [22]; coverage rates have been increas-
ing over the years. During this period, there were also
several government actions, including directives to re-
duce the target age group, and there was considerable
controversy involving the Brazilian Society of Radiology
and the Brazilian Society of Mastology in this regard.
From 2010, this opportunistic mammography screening
programme in the RHD of Barretos had a differential
structure that approximated an organised screening
programme; therefore, it was unique in Brazil. As a ter-
tiary level hospital, the Barretos Cancer Hospital is re-
sponsible for conducting mammography screening,
complementary tests, medical care, diagnosis, treatment,
and follow-up of patients. Mammograms can be per-
formed either at the Department of Prevention (Barretos
Cancer Hospital) or at the Mobile Health Unit that regu-
larly visits the cities of the region sequentially, remaining
for 3–5 days in each town. In this opportunistic mam-
mography screening programme in the RHD of Barretos,
women ranging in age between 40 and 49 years are of-
fered annual mammography, while women ranging in
age between 50 and 69 years are provided biannual
mammography. While it is likely that higher screening
Table 2 Breast and cervical cancer incidence rates and mortality rates per 100,000 women according to the Population-Based
Cancer Registry of Barretos Cancer Hospital, São Paulo, Brazil, years 2000–2015
Year Breast cancer Cervical cancer
In Situ Incidence (D05) Invasive Incidence (C50) Mortality M:Ia In Situ Incidence (D06) Invasive Incidence (C53) Mortality M:Ia
2000 1.55 29.09 10.04 0.34 10.90 10.67 4.32 0.40
2001 4.16 36.54 11.59 0.32 21.13 13.29 3.72 0.28
2002 4.30 34.51 9.52 0.28 11.00 13.42 3.37 0.25
2003 1.90 37.51 14.05 0.37 7.29 10.33 6.27 0.61
2004 4.10 45.08 17.46 0.39 5.87 12.79 7.28 0.57
2005 7.30 44.92 12.63 0.28 10.84 9.29 2.43 0.26
2006 11.02 56.30 10.28 0.18 8.11 9.75 5.81 0.60
2007 11.90 35.89 10.07 0.28 7.51 7.23 4.01 0.55
2008 5.55 36.52 10.35 0.28 4.51 5.72 2.10 0.37
2009 8.34 34.20 9.43 0.27 8.67 6.57 2.04 0.31
2010 10.21 48.02 11.27 0.23 11.74 5.98 2.00 0.33
2011 10.99 45.92 11.59 0.25 21.38 7.19 2.21 0.31
2012 14.78 61.61 10.01 0.16 35.00 11.82 1.86 0.16
2013 14.62 58.63 13.75 0.23 41.82 10.37 3.36 0.32
2014 13.96 61.70 11.74 0.19 33.01 10.75 2.78 0.26
2015 16.04 64.09 14.00 0.22 24.84 8.87 3.13 0.35























ASR age-standardized rate (world population), M:I mortality-to-invasive incidence ratio, AAPC average annual percentage change, CI confidence interval, NA
not applicable
aIncludes ratio of mortality-to-overall incidence of invasive breast or cervical cancer, respectively
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Fig. 1 Joinpoint analysis of breast cancer, years 2000–2015. a In situ incidence; (b) invasive incidence; (c) mortality
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Fig. 2 Joinpoint analysis of cervical cancer, years 2000–2015. a In situ incidence; (b) invasive incidence; (c) mortality
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coverage played a role in the increase in breast cancer
incidence, the reductions of invasive breast cancer
mortality-to-incidence ratio and survival rate during the
study period also likely reflect better cancer outcomes
for these patients and higher treatment availability in the
Barretos RHD.
While some of the increase in breast cancer incidence
rates can be explained by increased surveillance, the in-
crease in invasive cancer (4.3%) cannot be explained by
screening alone. Worldwide breast cancer incidence has
increased by over 20% since GLOBOCAN 2008 [1, 23],
and many of the countries with increased breast cancer
rates, such as the UK and US, already had breast cancer
screening programmes. This trend of increasing breast
cancer incidence in the range of 4% to 10% has also been
observed in other countries that have transitioned from
low income to middle income (such as Philippines,
Columbia, and Costa Rica) or from middle income to
high income (such as Israel and the Czech Republic) [20,
24]. These findings might be attributable to lifestyle
changes associated with higher economic development,
such as women having fewer children and prolonged age
at first birth, and increased use of oral contraception
[25]. Other lifestyle changes can also be due to increases
in the prevalence of lifestyle risk factors, such as obesity
and low levels of physical activity [26].
Our present study indicates a significant increase in the
incidence of cervical cancer and a decrease in mortality
due to cervical cancer in the RHD of Barretos in recent
years. Improvements in Brazilian government strategies
most likely have influenced these trends as well as the in-
stallation of the Organized Cervical Cancer Screening Pro-
gram in the RHD of Barretos. Cytology using Pap smear
tests is the screening method offered to all women aged
25–64 years who are sexually active according to the
Brazilian Guidelines for Cervical Cancer Screening [21].
Since 1994, the Barretos Cancer Hospital has introduced
the use of mobile units that offer cervical cancer screening
to the target population of the RHD [27]. From 2012,
women aged between 25 and 64 years are invited annually
to participate in the cervical cancer prevention programme
via municipality-specific health service units [28]. Letters
are mailed to all women who were already registered in a
database and who were not up-to-date on their Pap smear,
as well as women for whom a Pap smear should be re-
peated when the mobile unit is present in their municipal-
ity [28]. The invitations are sent to women following the
screening protocol, and the exams are routinely conducted
at intervals of 3 years after two annual negative exams [28].
A systematic follow-up of the women participating in the
cervical cancer screening programme is performed using
software developed by the Barretos Cancer Hospital for
this purpose [28]. However, this government lacks reliable
information on coverage rate, which is essential for
programme monitoring, and future studies are needed to
monitor the prevalence of abnormal cytology screening re-
sults and to quantify the effectiveness of cervical cancer
screening in Brazil since the introduction of this screening
programme.
A significant strength of this study is the multiple
measures taken to accurately capture the cancer in-
cidence and mortality of over 200,000 women living
in the Barretos RHD. As the Population-Based Can-
cer Registry data of Barretos Cancer Hospital were
retrieved from several different sources of informa-
tion, some cases could be found in more than one
information source. Extra care was taken to avoid
duplication of registered cases. Many patients de-
clared their residence in Barretos, which is the head-
quarters of one of the largest centres for cancer
Table 3 Overall survival rates according to the Population-Based Cancer Registry of Barretos Cancer Hospital, São Paulo, Brazil, years
2000–2015
Variable Breast cancer Cervical cancer
Cases Deaths 5-y OS pa HR (95% CI) Cases Deaths 5-y OS pa HR (95% CI)
Overall survival 2110 597 74.3 – – 978 200 70.7 – –
Year of Diagnoses
2000–2004 410 204 67.1 0.058 Reference 249 90 68.3 0.004 Reference
2005–2009 596 194 77.5 0.797 (0.648; 0.980) 185 51 64.2 1.214 (0.848; 1.739)
2010–2015 1104 199 75.0 0.801 (0.645; 0.996) 551 59 73.4 0.652 (0.456; 0.932)
Clinical stage of disease at Diagnosis (Breast cancer: TNM; Cervical Cancer: FIGO)
In situ 338 26 96.0 < 0.001 0.035 (0.023; 0.053) 619 26 93.6 < 0.001 0.023 (0.014; 0.038)
I 468 61 89.4 0.061 (0.045; 0.082) 84 14 87.3 0.051 (0.027; 0.095)
II 649 154 81.9 0.097 (0.077; 0.121) 91 29 61.0 0.133 (0.082; 0.216)
III 405 184 57.3 0.269 (0.216; 0.334) 94 63 34.3 0.362 (0.245; 0.536)
IV 183 154 12.3 Reference 51 46 5.1 Reference
aKaplan-Meier; HR hazard ratio, CI confidence interval. 5-y OS, 5-year overall survival
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treatment in Brazil, which could artificially increase
cancer incidence rates in the region. We identified
and confirmed cases from the geographical area of
the cancer registry by reviewing the primary sources
of information to mitigate this issue. The mortality
rates were calculated from death records of the
DATASUS. The cause of death registration in this
database has been described as being imprecise,
mainly in rural areas, which can jeopardise our con-
clusions. The indicators would be higher than those
officially disclosed if corrections were made regard-
ing undefined deaths and cases classified as a
non-specified area of the uterus. However, official
data were used, and all possible effort was aimed at
improving the quality of information.
Conclusion
Our study demonstrates that breast and cervical can-
cer incidence rates were increasing over time between
2000 and 2015 in the RHD of Barretos (São Paulo).
The mortality trends did not significantly increase for
breast cancer, while for cervical cancer there were
statistically significant decreases in mortality over
time, likely due to the implementation of screening
and the availability of treatment. For breast cancer,
the increasing incidence trend could not be explained
by screening alone, but it may be due to changes in
the prevalence of lifestyle risk factors in the Barretos
RHD. The survival rate of these women improved
over time.
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